• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Gossamer Bio, Inc. - Common Stock (NQ:GOSS)

    0.4095 +0.0379 (+10.20%)
    Official Closing Price Updated: 4:15 PM EDT, Apr 10, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Gossamer Bio, Inc. - Common Stock

    < Previous 1 2 3 4 5 6 7 8 9 Next >
    News headline image
    GOSS Investors Have Opportunity to Lead Gossamer Bio, Inc. Securities Fraud Lawsuit with the Schall Law Firm
    From Schall Law
    Via GlobeNewswire
    News headline image
    Deadline Approaching: Gossamer Bio, Inc. (GOSS) Shareholders Who Lost Money Urged To Contact Law Offices of Howard G. Smith
    From Law Offices of Howard G. Smith
    Via Business Wire
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Gossamer Bio, Inc. of Class Action Lawsuit and Upcoming Deadlines – GOSS
    From Pomerantz LLP
    Via GlobeNewswire
    News headline image
    GOSS Investor Alert: Gossamer Bio Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Company Allegedly Overstated Trial Prospects: Levi & Korsinsky
    From Levi & Korsinsky, LLP
    Via Business Wire
    News headline image
    Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm Encourages Gossamer Bio, Inc. (GOSS) Shareholders To Inquire About Securities Fraud Class Action
    From Glancy Prongay Wolke & Rotter LLP
    Via Business Wire
    News headline image
    GOSS Investors Have Opportunity to Lead Gossamer Bio, Inc. Securities Fraud Lawsuit with the Schall Law Firm
    From Schall Law
    Via GlobeNewswire
    News headline image
    Law Offices of Frank R. Cruz Encourages Gossamer Bio, Inc. (GOSS) Shareholders To Inquire About Securities Fraud Class Action
    From The Law Offices of Frank R. Cruz
    Via Business Wire
    News headline image
    Law Offices of Howard G. Smith Encourages Gossamer Bio, Inc. (GOSS) Shareholders To Inquire About Securities Fraud Class Action
    From Law Offices of Howard G. Smith
    Via Business Wire
    News headline image
    Securities Fraud Investigation Into Gossamer Bio, Inc. (GOSS) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm
    From Glancy Prongay Wolke & Rotter LLP
    Via Business Wire
    News headline image
    Gossamer Bio, Inc. (GOSS) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
    From Law Offices of Howard G. Smith
    Via Business Wire
    News headline image
    GOSS Investors Have Opportunity to Lead Gossamer Bio, Inc. Securities Fraud Lawsuit with the Schall Law Firm
    From Schall Law
    Via GlobeNewswire
    News headline image
    Gossamer Bio, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – GOSS
    From DJS LAW GROUP
    Via Business Wire
    News headline image
    Securities Fraud Investigation Into Gossamer Bio, Inc. (GOSS) Announced – Shareholders Who Lost Money Urged to Contact The Law Offices of Frank R. Cruz
    From The Law Offices of Frank R. Cruz
    Via Business Wire
    News headline image
    GOSS Investors Have Opportunity to Lead Gossamer Bio, Inc. Securities Fraud Lawsuit with the Schall Law Firm
    From The Schall Law Firm
    Via Business Wire
    News headline image
    Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Gossamer Bio, Inc. (NASDAQ:GOSS) and Encourages Investors with Large Losses to Contact the Firm
    From Bragar Eagel & Squire
    Via GlobeNewswire
    News headline image
    Investor Notice: Robbins LLP Informs Investors of the Gossamer Bio, Inc. Class Action Lawsuit
    From Robbins LLP
    Via Business Wire
    News headline image
    GOSS DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Gossamer Bio (GOSS) Investors of Securities Class Action Deadline on June 1, 2026
    From Faruqi & Faruqi LLP
    Via GlobeNewswire
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Gossamer Bio, Inc. – GOSS
    From Pomerantz LLP
    Via GlobeNewswire
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gossamer Bio, Inc. - GOSS
    From Pomerantz LLP
    Via GlobeNewswire
    News headline image
    Gossamer Bio Announces Fourth Quarter and Full-Year 2025 Financial Results and Provides Corporate Update
    From Gossamer Bio, Inc.
    Via Business Wire
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gossamer Bio, Inc. - GOSS
    From Pomerantz LLP
    Via GlobeNewswire
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gossamer Bio, Inc. - GOSS
    From Pomerantz LLP
    Via GlobeNewswire
    News headline image
    GOSS Investors Have Opportunity to Join Gossamer Bio, Inc. Fraud Investigation with the Schall Law Firm
    From The Schall Law Firm
    Via Business Wire
    These stocks are the most active in today's session ↗
    Via Chartmill
    The trading volume of these stocks is deviating from the norm in today's session. ↗
    Via Chartmill
    In today's session, these stocks are experiencing unusual volume. ↗
    Via Chartmill
    Check out the stocks that are attracting the most attention and driving market activity. ↗
    Via Chartmill
    News headline image
    Gossamer Bio Stock Plummeted 82% Today — What’s Behind The Crash? ↗
    Gossamer Bio’s seralutinib did not achieve the predefined statistical bar for its main goal in the phase 3 PROSERA trial. 
    Via Stocktwits
    These stocks are gapping in today's session ↗
    Via Chartmill
    News headline image
    Gossamer Bio Announces Topline Results from the Phase 3 PROSERA Study Evaluating Seralutinib in Pulmonary Arterial Hypertension
    From Gossamer Bio, Inc.
    Via Business Wire
    < Previous 1 2 3 4 5 6 7 8 9 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.